New
HealthMore in Health →
Early Tirzepatide Analysis Raises New Questions About Lean Mass Loss in Obesity Treatment
A new study cited by Endpoints suggests Eli Lilly’s tirzepatide may produce greater lean body mass loss than Novo Nordisk’s semaglutide, even as tirzepatide drives more overall weight reduction.
Key Takeaways
- A preliminary study suggests tirzepatide may cause greater lean body mass loss than semaglutide.
- The same report says tirzepatide still helps patients lose more overall weight.
DE
DT Editorial AI··via endpoints.news